

# Genetic Determinants of CAR T-Cell Therapy Outcomes: A Comparative Analysis of DLBCL and Glioblastoma

Anika M. Huralikoppi

*Gwinnett School of Mathematics, Science, and Technology,  
970 McElvaney Ln NW, Lawrenceville, GA 30044, United States*

## ABSTRACT

CAR T-cell therapy has become a revolutionary option for patients with certain cancers, but its effectiveness remains uneven across cancer types. This study is particularly interested in why CAR T treatment produces stronger and more durable responses in diffuse large B-cell lymphoma (DLBCL), compared to glioblastoma (GBM). It is hypothesised that differences in the genetic mutations commonly found in each cancer may underlie these differences in treatment response. To investigate this, cBioPortal is used, an open-access cancer genomics database, to analyze the mutation and clinical data of patients with DLBCL (n=2143) and GBM (n=881), respectively. Because patient-level genomic data from CAR T clinical trials is not directly available, a matching process was created to align real-world patient data from cBioPortal with the demographic and clinical characteristics reported in trial populations. Using this matched dataset, a survival analysis was performed to examine how specific genetic mutations may be associated with patient outcomes after CAR T therapy. Our findings suggest that while DLBCL patients with mutations in genes like PIM1 and IGHV2-70 had poorer survival, GBM patients with EGFR and PIK3R1 mutations faced even worse prognoses. These patterns, combined with factors like heterogeneity in cell-surface antigens and tumor location, help explain why CAR T therapy remains far more effective in blood cancers than in solid tumors like GBM. By identifying genetic profiles associated with survival outcomes, our study may inform future iterations of CAR T design and provide insights to predict the efficacy of CAR T therapy, especially for solid tumors.

**Keywords:** Oncology; Cancer; Neuroscience; CAR-T; Glioblastoma; Diffuse Large B-cell Lymphoma

## INTRODUCTION

Chimeric Antigen Receptor T-cell (CAR T) therapy is a form of immunotherapy that modifies a patient's

own T cells to recognize and destroy cancer cells. The process involves extracting T cells, engineering them to express receptors, expanding them in the lab, and infusing them back into the patient. This approach has shown promise in hematologic malignancies, especially B-cell cancers. In relapsed or refractory diffuse large B-cell lymphoma (DLBCL), for example, CAR T-cell therapy has demonstrated a complete response (CR) rate of 54%, with 40% of patients maintaining remissions beyond two years (1). However, the success of CAR T therapy is far more limited in other solid tumors (2).

---

**Corresponding author:** Anika M. Huralikoppi, E-mail: [anikahuralikoppi@gmail.com](mailto:anikahuralikoppi@gmail.com).

**Copyright:** © 2025 Anika M. Huralikoppi. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Accepted** October 21, 2025

<https://doi.org/10.70251/HYJR2348.359981008>

Since CAR T cells typically target CD19, a surface protein expressed on B cells, genetic mutations in immunoglobulin-related genes like IGHV2-70, which are involved in B-cell receptor formation, may influence both disease progression and response to CAR T-cell therapy (3).

DLBCL, the most common type of non-Hodgkin lymphoma, accounts for 30–40% of all cases globally. It is an aggressive cancer of mature B cells, often presenting with rapidly growing lymph nodes and systemic symptoms. While first-line treatment with the R-CHOP regimen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone, cures approximately 60–70% of patients, a significant proportion either relapse or fail to respond (4). The consistent expression of CD19 on malignant B cells makes DLBCL an ideal candidate for CD19-directed CAR T therapies, such as Yescarta and Kymriah, both of which are FDA-approved for use in relapsed or refractory DLBCL. Yescarta showed an overall response rate of 82% and complete response rate of 54% in real-world data (5). Immune checkpoint inhibitors (ICIs) have been explored in DLBCL as well, particularly PD-1 blockade with nivolumab or pembrolizumab, but results have been limited, with single-agent response rates typically under 40% (6). Ongoing trials are evaluating ICIs efficacy in combination with chemotherapy or other immunotherapies. Genetically, DLBCL is heterogeneous, and it can be categorized into subtypes like germinal center B-cell-like (GCB) and activated B-cell-like (ABC), each with distinct molecular pathways and treatment responses (7).

In contrast to DLBCL where CAR T-cell therapy has shown success, other solid tumors pose unique challenges. Among solid tumors, Glioblastoma (GBM) stands out as a particularly aggressive cancer, making it an important candidate for investigation. GBM is a highly aggressive primary brain tumor with a median survival time of only 15 to 18 months despite standard treatment involving surgical resection, radiation, and chemotherapy with temozolomide (8). GBM poses significant therapeutic challenges due to its extensive heterogeneity in genetic profiles and the tumor ecosystem, its resistance to treatment, and the presence of the blood-brain barrier, which limits drug and immune cell access. While CAR T therapy has been tested in GBM, mainly targeting EGFRvIII, clinical trials have shown limited efficacy, with no sustained responses and median progression-free survival of only 1.3 months (7). Immune checkpoint inhibitors have also

been developed and tested for GBM, especially PD-1 and CTLA-4 inhibitors like nivolumab and ipilimumab, but they have not been effective, due to low tumor mutational burden, poor T-cell infiltration, and an immunosuppressive environment (9). However, unlike in melanoma or non-small cell lung cancer, ICIs have failed to significantly improve survival in GBM (10).

CAR T-cell therapy is significantly more effective in DLBCL than in GBM. In DLBCL, complete response rates reach up to 54%, with many patients achieving long-term remission, largely due to uniform CD19 expression, better CAR T-cell expansion, and a less immunosuppressive tumor environment. In contrast, GBM exhibits poor CAR T efficacy, with low response rates and short progression-free survival. This is due to antigen heterogeneity (e.g., variable EGFRvIII or IL13R $\alpha$ 2 expression), immune evasion mechanisms, and physical barriers like the blood-brain barrier (7). Additionally, the GBM microenvironment contains suppressive myeloid cells that hinder CAR T-cell activity (11). While these tumor-level and microenvironmental challenges play a major role, underlying genetic differences between DLBCL and GBM may further influence treatment response, shaping both tumor behavior and susceptibility to CAR T-cell therapy. These differences suggest that genetics may be critical to understanding why CAR T-cell therapy is more successful in DLBCL than GBM.

To knowledge, no head-to-head genomic studies have compared CAR T-cell factors in DLBCL versus GBM. The study aims to investigate whether genetic differences between DLBCL and GBM can help explain the contrast in CAR T-cell therapy effectiveness. It is hypothesized that specific mutations in GBM may hinder CAR T efficacy but these are not present in DLBCL. By using publicly available datasets from cBioPortal and other sources, this study offers insights that could guide the development of future CAR T therapies for solid tumors.

## METHODS AND MATERIALS

To allow for proper comparison between cBioPortal patient datasets and clinical trial populations used in CAR-T studies, where individual genetic information is unavailable, for DLBCL and GBM, a matching process was designed based on available demographic and clinical data in both datasets. This process involved extracting summary statistics of patient characteristics from the trials, defining a distance function of the

patient characteristics, and selecting subsamples from cBioPortal that closely matched the clinical trial populations based on the distance function.

### Clinical Trial Reference Statistics

Trial demographic and disease characteristics were extracted from published studies (1, 12-24) and standardized. For continuous variables (e.g., age, Karnofsky score), weighted medians were calculated. For categorical variables (e.g., sex, disease stage), sample-size proportions were used. Separate standardization was used for DLBCL and GBM. Patients were excluded if more than 50% of the characteristics are missing. Pediatric GBM patients were also excluded due to known differences in genetic profiles between adult and pediatric GBM patients (25). Patient age was assumed to be reported at the beginning of the trials.

To quantify similarity between a subsample and its corresponding clinical trial population, a distance function was defined. This function accounts for both categorical and continuous variables after scaling and standardizing the data.

Because individual CAR T-cell treatment data is not available in cBioPortal, survival outcomes were derived using the clinical information provided within each study's dataset. For both DLBCL and GBM cohorts, overall survival (OS) and progression-free survival (PFS) variables were extracted directly from the "Clinical Data" tables of the respective cBioPortal studies and incorporated during subsampling to ensure that selected patients matched the clinical trial populations in available survival follow-up. The data reflects outcomes under standard-of-care or trial-reported therapies rather than CAR T-specific results. This allowed indirect evaluation of genomic and clinical predictors of survival within populations demographically matched to CAR-T trial participants, providing a reference baseline for interpreting potential CAR-T response patterns when matched.

An algorithm was implemented to identify the optimal subset from the cBioPortal dataset that minimized the defined distance to the clinical trial reference statistics. At each iteration: A candidate subsample of size "n" was drawn without replacement. The distance to the clinical trial reference was computed. The best subsample for each "n" was noted. This process was repeated across a range of "n" values, and the overall best subsample was selected as the one with the lowest distance.

Mutation data for DLBCL and GBM were

downloaded from cBioPortal. Both the complete and subsampled datasets were processed and analyzed. After removing synonymous mutations, metrics were computed for each cancer type, including the ten most frequently mutated genes, the distribution of mutation types (e.g., single-nucleotide polymorphisms, deletions, and insertions), and the distribution of variant classifications (e.g., missense, nonsense, and frameshift mutations).

For both DLBCL and GBM, three primary data frames were constructed. The first contained patient-level survival information, including overall survival time, progression-free survival time, and event status, defined as either death or disease progression. When available, both overall and progression-free survival data were incorporated. The second data frame summarized clinical characteristics. For DLBCL, these features included age at diagnosis, sex, stage III or IV disease status, and the International Prognostic Index (IPI) score. For GBM, clinical variables included age at diagnosis, sex, disease stage, and Karnofsky performance score. The third data frame captured mutation status for the ten most frequently mutated genes in each cancer type, coded as binary variables (0 = absent, 1 = present).

The mutation matrix and patient characteristics were merged based on patient IDs. To ensure equal weighting of characteristics, continuous variables were scaled by subtracting the mean (of the entire dataset for a cancer) and dividing by the standard deviation (of the entire dataset for a cancer) within each iteration. Mutation columns were also scaled to match continuous variables. The final dataset (merged survival, characteristics, and mutations) was prepared for Cox Modeling. Cox proportional hazards models were made separately for DLBCL and GBM datasets using the lifelines Python package (26). The models included both clinical variables and genetic mutation statuses. Hazard ratio (HR), 95% confidence intervals, and p-values were computed for each predictor.

## RESULTS

### Patient Matching

To perform joint analysis of genetic mutations and CAR T therapy treatment outcomes on the same individuals, subsets of cBioPortal patients were matched in terms of patient characteristics with patients who underwent CAR T clinical trials. This is because cBioPortal provides individual-level genetic mutations

from many patients, but most patients did not go through clinical trials. The existing clinical trials tend to be small and typically do not make individual-level genetic mutations available. By minimizing demographic and clinical differences between subsampled patient cohorts in cBioPortal and the overall populations within the clinical trials, the goal was to approximate the CAR T treatment outcome of the subsampled cBioPortal patients for each cancer.

Trial reference statistics guided subsampling of cBioPortal patients to approximate clinical trial populations (Tables 1-2). In DLBCL trials, the median patient age was 60, with 80.4% of participants presenting with stage III/IV disease and 50.5% of

participants with an International Prognostic Index (IPI) score of 3-5. For GBM trials, median age was 52.7, with an average Karnofsky performance score of 80.8.

Using distance-based matching, minimal distances were achieved: 2.697 for DLBCL and 2.836 for GBM. This yielded subsample sizes of n = 74 for DLBCL and n = 80 for GBM. The age and performance score distributions of matched and full cohorts closely overlap, confirming successful alignment of clinical characteristics (Figure 1A-D). Wilcoxon rank-sum tests also confirmed no significant differences in age or prognostic indices (DLBCL IPI: p = 0.59; GBM Karnofsky: p = 0.13), indicating that the matched samples closely represented their respective reference populations.

**Table 1.** Summary of diffuse large B-cell lymphoma (DLBCL) patient populations from CAR T-cell therapy clinical trials. Median age, sex distribution, stage III/IV status, and International Prognostic Index (IPI) scores are shown. Percent missing was calculated after removing patients missing 50% or more of characteristics.

Reference Statistics for DLBCL		
Characteristic	Statistic	% Missing
Median Age	60 years	21.5%
Stage III/IV	80.4%	17.1%
IPI High-Risk (Score 3-5)	50.5%	13.1%
Ann Arbor Stage III-IV	68%	23.0%
Male Sex	66%	10.3%

\*Statistic column was calculated after removing patients missing more than 50% of characteristics.

**Table 2.** Summary of glioblastoma (GBM) patient populations from CAR T-cell therapy clinical trials. Median age, sex distribution, tumor stage, and Karnofsky performance score are listed. Percent missing was calculated after removing patients missing 50% or more of characteristics.

Reference Statistics for GBM		
Characteristic	Statistic	% Missing
Median Age	52.7 years	2.5%
Stage III/IV	80.8%	20.2%
Male Sex	51.9%	27.3%
Karnofsky Performance Score	80.8	37.1%

\*Statistic column was calculated after removing patients missing more than 50% of characteristics.


### Top 10 Genes

Identifying the most frequently mutated genes in each cancer type provides insights into potential drivers of disease progression and resistance to CAR T-cell therapy. After removing synonymous mutations, the dataset contained 2,346 unique mutated genes in DLBCL and 1,857 in GBM.

The ten most frequently mutated genes identified in diffuse large B-cell lymphoma (DLBCL) patients (total of 2,346 unique mutated genes). Most common mutations included PIM1, BCL2, PCLO, IGLL5, FAT4, CSMD3, BTG1, SGK1, KMT2D, IGHV2-70 (Table 3).

**Table 3.** The ten most frequently mutated genes identified in diffuse large B-cell lymphoma (DLBCL) patients (total of 2,346 unique mutated genes).

Top 10 Mutated Genes in DLBCL				
Gene	Full Data	Full Data %	Subsampled Data	Subsampled Data %
PIM1	241	24%	21	28%
BCL2	232	23%	17	22%
PCLO	184	18%	14	18%
IGLL5	143	14%	13	17%
FAT4	140	14%	10	13%
CSMD3	138	14%	10	13%
BTG1	138	14%	10	13%
SGK1	123	12%	8	11%
KMT2D	113	11%	8	11%
IGHV2-70	93	9%	6	8%



**Figure 1.** Distributions of patient characteristics between subsampled and full cohorts are aligned. (A) Age at diagnosis in diffuse large B-cell lymphoma (DLBCL), (B) International Prognostic Index (IPI) scores in DLBCL, (C) age at diagnosis in glioblastoma (GBM), and (D) Karnofsky performance scores in GBM. Distance-based matching minimized differences between cBioPortal subsamples and clinical trial reference populations (minimal distance = 2.697 for DLBCL; 2.836 for GBM), yielding matched sample sizes of  $n = 74$  (DLBCL) and  $n = 80$  (GBM). Wilcoxon rank-sum tests showed no significant differences in age distributions (DLBCL  $p = 0.59$ ; GBM  $p = 0.13$ ).

The ten most frequently mutated genes identified in GBM patients (total of 1,857 unique mutated genes after excluding synonymous mutations). Frequent mutations occurred in TP53, PTEN, EGFR, TTN, NF1, MUC16, PIK3R1, FLG, PIK3CA, RYR2 (Table 4).

Across both cancers, single nucleotide polymorphisms (SNPs) represented the majority of mutations, while insertions and deletions occurred less frequently (Tables 5–6). The relative proportions of mutation classes were consistent between full and subsampled cohorts, indicating that matching did not introduce bias in mutation types.

### Survival Analysis

To test the hypothesis of whether distinct genetic features are associated with CAR T therapy in DLBCL and GBM, a survival analysis was conducted to associate the presence or absence of mutations in top 10

most mutated genes and the clinical factors (e.g., age) with survival outcomes in DLBCL and GBM.

In DLBCL, mutations in PIM1 (HR = 3.11), CSMD3 (HR = 2.51), KMT2D (HR = 2.98), PCLO (HR = 2.11), and IGHV2-70 (HR = 2.24) are associated with significantly increased hazard ratios (HRs) (Figure 2), indicating a higher risk of death and lower efficacy of CAR T therapy (Figure 2). Age was also an important clinical predictor, with higher age associated with an increased hazard of death (HR = 2.13), confirming age as a significant variable in DLBCL prognosis. In GBM, MUC16 (HR = 2.19), EGFR (HR = 2.44), and PIK3R1 (HR = 1.99) had high HRs (Figure 3), showing an association with worse CAR T therapy outcomes (Figure 3). Age was also a statistically significant predictor of poorer prognosis in GBM (HR = 3.44), indicating that older patients face a significantly higher risk of death.

**Table 4.** The ten most frequently mutated genes identified in glioblastoma (GBM) patients (total of 1,857 unique mutated genes after excluding synonymous mutations).

Top 10 Mutated Genes in GBM				
Gene	Full Data	Full Data %	Subsampled Data	Subsampled Data %
TP53	142	21%	23	29%
PTEN	129	19%	13	16%
EGFR	117	17%	14	17%
TTN	117	17%	11	14%
NF1	71	11%	9	11%
MUC16	66	10%	6	8%
PIK3R1	49	7%	12	15%
FLG	48	7%	9	11%
PIK3CA	46	7%	6	8%
RYR2	42	6%	3	4%

\*Note that the top genes are those with the most number of mutations within the entire patient cohort in cBioPortal (or the subsampled patient cohort). For patients with multiple mutations in the same gene, each mutation was counted individually.


**Table 5.** Breakdown of mutation classes in the DLBCL dataset for full and subsampled data. SNPs made up the majority of mutations, with insertions and deletions comprising smaller proportions, similar across full and subsampled cohorts.

DLBCL_Variant_Classifications		
Variant_Classification	Full Data	Subsampled Data
Missense_Mutation	30241	486.0
Nonsense_Mutation	1910	44.0
Splice_Site	948	12.0
Frame_Shift_Del	719	6.0
Frame_Shift_Ins	531	6.0

**Table 6.** Breakdown of mutation classes in the GBM dataset for full and subsampled data. SNPs made up the majority of mutations, with insertions and deletions comprising smaller proportions, similar across full and subsampled cohorts.


GBM_Variant_Classifications		
Variant_Classification	Full Data	Subsampled Data
Missense_Mutation	14783	168.0
Nonsense_Mutation	946	10.0
Frame_Shift_Del	817	5.0
Splice_Site	446	4.0
In_Frame_Del	289	2.0

	coef	exp(coef)	se(coef)	coef lower 95%	coef upper 95%	exp(coef) lower 95%	exp(coef) upper 95%	cmp to	z	P	-log2(p)
PIM1	1.45	4.28	0.47	0.54	2.37	1.71	10.69	0.00	3.11	<0.005	9.08
BCL2	-0.32	0.73	0.30	-0.92	0.28	0.40	1.32	0.00	-1.05	0.29	1.76
PCLO	0.83	2.29	0.39	0.06	1.60	1.06	4.96	0.00	2.11	0.03	4.84
IGLL5	0.03	1.03	0.39	-0.73	0.79	0.48	2.21	0.00	0.08	0.94	0.09
FAT4	-0.01	0.99	0.35	-0.69	0.67	0.50	1.95	0.00	-0.03	0.98	0.03
CSMD3	1.25	3.49	0.50	0.28	2.23	1.32	9.27	0.00	2.51	0.01	6.38
BTG1	0.38	1.47	0.35	-0.30	1.07	0.74	2.93	0.00	1.09	0.27	1.87
SGK1	0.51	1.66	0.75	-0.97	1.98	0.38	7.25	0.00	0.67	0.50	0.99
KMT2D	1.16	3.19	0.39	0.40	1.92	1.49	6.85	0.00	2.98	<0.005	8.42
IGHV2-70	0.82	2.28	0.37	0.10	1.55	1.11	4.70	0.00	2.24	0.03	5.31
Age	0.81	2.24	0.38	0.06	1.55	1.07	4.71	0.00	2.13	0.03	4.91
IPI	-0.42	0.66	0.37	-1.15	0.32	0.32	1.37	0.00	-1.11	0.27	1.91
Sex	-0.04	0.96	0.32	-0.67	0.59	0.51	1.80	0.00	-0.12	0.90	0.15



**Figure 2.** Hazard ratios (HRs), 95% confidence intervals, and p-values for predictors of survival in DLBCL (n = 74). Significant risk factors included mutations in PIM1 (HR > 2, p < 0.05), CSMD3 (HR > 2, p < 0.05), KMT2D (HR > 2, p < 0.05), PCLO (HR > 2, p < 0.05), and IGHV2-70 (HR > 2, p < 0.05). Age was also a strong clinical predictor (HR = 2.24 per unit increase, p < 0.01).

	coef	exp(coef)	se(coef)	coef lower 95%	coef upper 95%	exp(coef) lower 95%	exp(coef) upper 95%	cmp to	z	P	-log2(p)
TP53	-0.05	0.95	0.18	-0.40	0.31	0.67	1.36	0.00	-0.27	0.79	0.34
PTEN	-0.11	0.90	0.15	-0.41	0.19	0.66	1.21	0.00	-0.72	0.47	1.08
EGFR	0.34	1.40	0.14	0.07	0.61	1.07	1.83	0.00	2.44	0.01	6.10
TTN	-0.24	0.79	0.22	-0.67	0.20	0.51	1.22	0.00	-1.06	0.29	1.78
NF1	-0.11	0.90	0.17	-0.44	0.22	0.64	1.25	0.00	-0.65	0.51	0.96
MUC16	0.45	1.57	0.21	0.05	0.85	1.05	2.35	0.00	2.19	0.03	5.13
PIK3R1	0.30	1.35	0.15	0.01	0.59	1.01	1.81	0.00	1.99	0.05	4.44
FLG	-0.24	0.78	0.20	-0.64	0.15	0.53	1.16	0.00	-1.22	0.22	2.18
PIK3CA	0.10	1.10	0.19	-0.28	0.47	0.76	1.60	0.00	0.51	0.61	0.71
RYR2	-0.08	0.93	0.15	-0.38	0.23	0.69	1.25	0.00	-0.49	0.62	0.69
Age	0.68	1.97	0.20	0.29	1.06	1.34	2.89	0.00	3.44	<0.005	10.75
Karnofsky	0.09	1.10	0.17	-0.25	0.43	0.78	1.54	0.00	0.54	0.59	0.76
Sex	0.21	1.24	0.32	-0.42	0.85	0.65	2.33	0.00	0.65	0.51	0.96



**Figure 3.** Hazard ratios (HRs), 95% confidence intervals, and p-values for predictors of survival in GBM (n = 80). Significant risk factors included mutations in MUC16 (HR ≈ 1.97, p < 0.05), EGFR (HR ≈ 1.97, p < 0.05), and PIK3R1 (HR ≈ 1.97, p < 0.05). Age at diagnosis was also a significant predictor, with older patients experiencing substantially higher risk of death.

Age at diagnosis remained a negative prognostic factor in both cancers. This trend is also generally observed across many cancer types, where advanced age is associated with poorer outcomes, potentially due to immunosenescence and changes in the tumor microenvironment that impair T-cell function and reduce CAR-T efficacy (27).

## DISCUSSION

In this study, the hypothesis that genetic differences between DLBCL and GBM help explain why CAR T-cell therapy is effective in some cancers but not others was tested. Using publicly available datasets from cBioPortal, mutation and clinical data from 74 DLBCL patients and 80 GBM patients were analyzed, selected through distance-based patient matching to reflect clinical trial populations. The top 10 most frequently mutated genes in each cancer type were identified, and a survival analysis was conducted to determine which genetic mutations were associated with worse prognosis.

In DLBCL, mutations in key genes play significant roles in disease progression. PIM1 mutations cause gain-of-function or constitutive kinase activation, enhancing cell proliferation and survival (11). Mutations in PCLO disrupt normal cellular communication (30). CSMD3 mutations impair tumor suppressor activity due to loss-of-function (31). KMT2D mutations affect histone methylation and transcriptional control, altering

gene expression (32). Mutations in IGHV2-70 impact immunoglobulin structure and function, disrupting B-cell receptor signaling (33). In GBM, mutations in several critical genes influence tumor progression. EGFR mutations are typically gain-of-function, driving uncontrolled cell proliferation (34). Disruption of mucin functions by MUC16 mutations may affect immune evasion and cell signaling (35). PIK3R1 mutations impair inhibitory control of the PI3K pathway, leading to AKT activation and increased cell survival (36). Hotspot mutations in PIK3CA result in gain-of-function, activating PI3K signaling and promoting cell survival and growth.

Age at diagnosis remained a negative prognostic factor in both cancers. This is also generally true in most cancers, which could influence the immune microenvironment and T-cell function, indirectly affecting CAR-T efficacy (27).

The PI3K/AKT/mTOR pathway is represented in both datasets through genes such as PTEN, PIK3CA, PIK3R1, and SGK1. This pathway promotes cell survival and proliferation, and its disruption has been shown to reduce CAR T-cell infiltration and contribute to resistance against immune-mediated killing (28). Receptor tyrosine kinase (RTK) and MAPK signaling pathways are affected by mutations in EGFR, NF1, and PIM1. These pathways enhance tumor growth and contribute to the formation of an immune-suppressive tumor microenvironment (29).

The genetic differences between DLBCL and GBM

provide important clues as to why CAR T-cell therapy is highly effective in one but not the other. In DLBCL, the most frequently mutated genes, PIM1, BCL2, and KMT2D, are involved in B-cell development, survival, and epigenetic regulation (37). Several mutations, including those in IGLL5 and IGHV2-70, affect immunoglobulin genes, which are closely tied to the cancer's origin in the immune system (38). These features make DLBCL well-suited for CAR T-cell therapies that target B-cell antigens like CD19, which are expressed on the surface of malignant cells (39). In contrast, GBM frequently has mutations in TP53, PTEN, EGFR, and NF1, which activate growth-promoting pathways such as RTK/MAPK and PI3K/AKT (34). These mutations drive rapid tumor progression and create conditions that prevent immune cell activity. For example, PTEN mutations have been associated with reduced T-cell infiltration and resistance to immunotherapy (40), while EGFR mutations contribute to immune evasion (41). GBM's location within the brain also limits immune cell access due to the blood-brain barrier and presents a challenge for CAR T-cell therapies (41).

This is an active research area. In DLBCL, FDA-approved CAR T therapies such as axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) target CD19, a B-cell surface antigen expressed in nearly all malignant B cells. Consistent with our findings, multiple genes related to B-cell functions, such as IGHV2-70, IGLL5, and PIM1, were identified in the DLBCL top gene and survival analysis. On the other hand, developing CAR T therapies for GBM is more challenging, as our study highlighted recurrent alterations in the PI3K/AKT/mTOR pathway (PIK3R1, PIK3CA, PTEN, SGK1) and the RTK/MAPK pathway (EGFR, NF1, PIM1). Likely due to the complexity and redundancy of these pathways, existing CAR T therapies that focus on targets such as EGFRvIII and IL13R $\alpha$ 2 have shown only limited effects. However, these antigens are often variably expressed, contributing to the limited efficacy of CAR T therapy in GBM. To overcome this limitation, researchers have begun testing multi-targeted strategies. In a study, researchers tested intraventricular CARv3-TEAM-E T cells, targeting EGFRvIII and wild-type EGFR, in three recurrent GBM patients. Treatment caused no severe toxicities, induced rapid tumor regression in all, but responses were short-lived in two. Activity was observed even without EGFRvIII expression (42) (Choi et al., 2024). These results suggest

that while promising strategies are emerging, a better genetic understanding of GBM will be critical for identifying stable and broadly effective CAR T-cell targets.

### Limitations

This study has several limitations: First, data availability was limited, particularly regarding clinical variables, which restricted the ability to fully match patients across groups. Additionally, the sample size for both DLBCL and GBM was relatively small, and this also caused a small number of mutations in the dataset after subsampling. Since the analysis was not based on patients from a single controlled trial, the comparison between cancer types is indirect. Some patient demographic data, such as race, was incomplete or missing altogether. Some of the studies were done in areas with the majority of patients being one race. Also, the cohort was mainly made up of patients with recurrent or refractory cancer as CAR-T is generally used as a second- or third-line treatment in most cancers. As a result, the representativeness of the cohort is limited, and the findings may not fully reflect the broader population of patients with DLBCL or GBM.

The long-term goal is to develop predictive models that use a patient's genetic profile to determine the likelihood of response to CAR T therapy. Cancer treatment decisions will significantly benefit from reliable tools that predict patient responses. For recurrent or refractory tumors, CAR T-cell therapy is often a last-resort option: one that is extremely costly but can produce remarkable, durable remissions in select patients. The long-term goal of this line of research is to develop predictive models that integrate a patient's genetic profile to estimate the likelihood of response to CAR T therapy. Such models would help clinicians identify patients most likely to benefit, while sparing others from unnecessary toxicity and expense.

### CONCLUSION

Developing predictive tools to guide CAR T-cell therapy requires overcoming several key limitations. Currently, the absence of genomic and clinical data directly linked to CAR T clinical trial participants restricts the ability to define precise genotype response relationships. In this study, this gap was addressed by designing a method to approximate trial populations through patient matching and by analyzing mutational patterns that may influence outcomes. While indirect,

this approach provides a foundational dataset and highlights genetic features that could be incorporated into future predictive models.

Moving forward, these findings can inform the design of multi-target CAR T therapies, particularly for solid tumors such as GBM, where concurrent mutations in the PI3K/AKT/mTOR and RTK/MAPK pathways contribute to immune resistance. Engineering CAR T constructs that simultaneously target multiple antigens or integrate checkpoint-modulating domains could help overcome this pathway redundancy and enhance persistence within the tumor microenvironment.

The development of predictive models that integrate genetic, clinical, and demographic variables could enable personalized patient selection by identifying individuals most likely to respond while avoiding unnecessary toxicity and cost. Achieving this will require expanded patient-level datasets that couple genomic profiles with detailed CAR T treatment information, response metrics, and long-term outcomes.

Future progress will depend on comprehensive datasets that combine patient-level clinical trial genomics with treatment response data. Such datasets would allow direct modeling of how tumor genetics influence CAR T efficacy across cancer types, enabling predictive algorithms. Ultimately, by combining mutation profiles with clinical trial data, these tools could transform patient selection, optimize resource use, and improve overall outcomes in CAR T-cell therapy.

## ACKNOWLEDGEMENTS

This project was completed under the guidance of a PhD student mentor, Yilan (Elain) Wang.

## CONFLICT OF INTERESTS

The author declares that there are no conflicts of interest related to this work.

## REFERENCES

1. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, *et al.* Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol.* 2019 Jan 1; 20 (1): 31-42.
2. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. *Nat Rev Clin Oncol.* 2020 Mar; 17 (3): 147-67. <https://doi.org/10.1038/s41571-019-0297-y>
3. Watson CT, Glanville J, Marasco WA. The Individual and Population Genetics of Antibody Immunity. *Trends Immunol.* 2017 July; 38 (7): 459-70. <https://doi.org/10.1016/j.it.2017.04.003>
4. Crump M, Neelapu SS, Farooq U, Van Den Neste E, *et al.* Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood.* 2017 Oct 19; 130 (16): 1800-8. <https://doi.org/10.1182/blood-2017-03-769620>
5. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, *et al.* Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. *J Clin Oncol.* 2020 Sept 20; 38 (27): 3119-28. <https://doi.org/10.1200/JCO.19.02104>
6. Ansell SM, Lesokhin AM, Borrello I, Halwani A, *et al.* PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *N Engl J Med.* 2015 Jan 22; 372 (4): 311-9. <https://doi.org/10.1056/NEJMoa1411087>
7. Chapuy B, Stewart C, Dunford AJ, Kim J, *et al.* Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med.* 2018 May; 24 (5): 679-90.
8. Stupp R, Mason WP, Bent MJ van den, Weller M, *et al.* Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. *N Engl J Med.* 2005 Mar 10; 352 (10): 987-96. <https://doi.org/10.1056/NEJMoa043330>
9. Reardon DA, Freeman G, Wu C, Chiocca EA, *et al.* Immunotherapy advances for glioblastoma. *Neuro-Oncol.* 2014 Nov; 16 (11): 1441-58. <https://doi.org/10.1093/neuonc/nou212>
10. Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. *Cell Mol Immunol.* 2024 Dec; 21 (12): 1354-75. <https://doi.org/10.1038/s41423-024-01226-x>
11. Huang B, Zhang J, Zong W, Chen S, *et al.* Myeloid cells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. *Front Immunol.* 2023 Feb 27; 14: 994698. <https://doi.org/10.3389/fimmu.2023.994698>
12. Abramson JS, Solomon SR, Arnason J, Johnston PB, *et al.* Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. *Blood.* 2023 Apr 6; 141 (14): 1675-84. <https://doi.org/10.1182/blood.2022018730>
13. Majzner RG, Ramakrishna S, Yeom KW, Patel S, *et al.*

- GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. *Nature*. 2022 Mar; 603 (7903): 934-41. <https://doi.org/10.1038/s41586-022-04489-4>
14. Ahmed N, Brawley V, Hegde M, Bielanowicz K, *et al.* HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. *JAMA Oncol*. 2017 Aug 1; 3 (8): 1094-101. <https://doi.org/10.1001/jamaoncol.2017.0184>
  15. Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, *et al.* Locoregional delivery of IL-13R $\alpha$ 2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. *Nat Med*. 2024 Apr; 30 (4): 1001-12. <https://doi.org/10.1038/s41591-024-02875-1>
  16. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, *et al.* Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*. 2017 Dec 28; 377 (26): 2531-44.
  17. Schuster SJ, Bishop MR, Tam CS, Waller EK, *et al.* Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2019 Jan 3; 380 (1): 45-56. <https://doi.org/10.1056/NEJMoa1804980>
  18. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, *et al.* Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2022 Dec 14; 387 (24): 2220-31. <https://doi.org/10.1056/NEJMoa2206913>
  19. Turtle CJ, Hay KA, Hanafi LA, Li D, *et al.* Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. *J Clin Oncol Off J Am Soc Clin Oncol*. 2017 Sept 10; 35 (26): 3010-20. <https://doi.org/10.1200/JCO.2017.72.8519>
  20. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, *et al.* Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nat Med*. 2018 May; 24 (5): 563-71. <https://doi.org/10.1038/s41591-018-0010-1>
  21. Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, *et al.* Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. *Blood*. 2023 May 11; 141 (19): 2307-15. <https://doi.org/10.1182/blood.2022018893>
  22. Maude SL, Laetsch TW, Buechner J, Rives S, *et al.* Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med*. 2018 Feb 1; 378 (5): 439-48.
  23. Abramson JS, Solomon SR, Arnason J, Johnston PB, *et al.* Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. *Blood*. 2023 Apr 6; 141 (14): 1675-84. <https://doi.org/10.1182/blood.2022018730>
  24. Gauthier J, Gazeau N, Hirayama AV, Hill JA, *et al.* Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. *Blood*. 2022 June 30; 139 (26): 3722-31. <https://doi.org/10.1182/blood.2021014497>
  25. Sturm D, Bender S, Jones DTW, Lichter P, *et al.* Paediatric and adult glioblastoma: multifiform (epi) genomic culprits emerge. *Nat Rev Cancer*. 2014 Feb; 14 (2): 92-107. <https://doi.org/10.1038/nrc3655>
  26. Davidson-Pilon C. lifelines: survival analysis in Python. *J Open Source Softw*. 2019 Aug 4; 4 (40): 1317. <https://doi.org/10.21105/joss.01317>
  27. Ferrucci L, Gonzalez-Freire M, Fabbri E, Simonsick E, *et al.* Measuring biological aging in humans: A quest. *Aging Cell*. 2020 Feb; 19 (2): e13080. <https://doi.org/10.1111/acel.13080>
  28. Glaviano A, Foo ASC, Lam HY, Yap KCH, *et al.* PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. *Mol Cancer*. 2023 Aug 18; 22 (1): 138. <https://doi.org/10.1186/s12943-023-01827-6>
  29. Lailler C, Louandre C, Morisse MC, Lhossein T, *et al.* ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma. *Biosci Rep*. 2019 Sept 13; 39 (9): BSR20191433. <https://doi.org/10.1042/BSR20191433>
  30. Liu Y, Zhang Y, Zhu L, Zhou Z, *et al.* PCLO Is Associated with Tumor Mutational Burden and Immunity in Patients with Oral Squamous Cell Carcinoma. *Curr Issues Mol Biol*. 2025 June 6; 47 (6): 426. <https://doi.org/10.3390/cimb47060426>
  31. Lu N, Liu J, Xu M, Liang J, *et al.* CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients. *Int J Gen Med*. 2021; 14: 7647-57. <https://doi.org/10.2147/IJGM.S335592>
  32. Ortega-Molina A, Boss IW, Canela A, Pan H, *et al.* The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. *Nat Med*. 2015 Oct; 21 (10): 1199-208. <https://doi.org/10.1038/nm.3943>
  33. Davis RE, Ngo VN, Lenz G, Tolar P, *et al.* Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature*. 2010 Jan; 463 (7277): 88-92. <https://doi.org/10.1038/nature08638>
  34. Brennan CW, Verhaak RGW, McKenna A, Campos B, *et al.* The Somatic Genomic Landscape of Glioblastoma. *Cell*. 2013 Oct 10; 155 (2): 462-77.
  35. Wang Z, Hou H, Zhang H, Duan X, Li L, Meng L.

- Effect of MUC16 mutations on tumor mutation burden and its potential prognostic significance for cutaneous melanoma. *Am J Transl Res.* 2022 Feb 15; 14 (2): 849-62.
36. McLendon R, Friedman A, Bigner D, Van Meir EG, *et al.* Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature.* 2008 Oct; 455 (7216): 1061-8. <https://doi.org/10.1038/nature07385>
37. Zhang J, Grubor V, Love CL, Banerjee A, *et al.* Genetic heterogeneity of diffuse large B-cell lymphoma. *Proc Natl Acad Sci.* 2013 Jan 22; 110 (4): 1398-403. <https://doi.org/10.1073/pnas.1205299110>
38. Evrard SM, Péricart S, Grand D, Amara N, *et al.* Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. *Haematologica.* 2019 Apr; 104 (4): e154-7. <https://doi.org/10.3324/haematol.2018.198572>
39. Schuster SJ, Svoboda J, Chong EA, Nasta SD, *et al.* Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. *N Engl J Med.* 2017 Dec 28; 377 (26): 2545-54. <https://doi.org/10.1056/NEJMoal708566>
40. Peng W, Chen JQ, Liu C, Malu S, *et al.* Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. *Cancer Discov.* 2016 Feb; 6 (2): 202-16.
41. Ijaz M, Tan Q, Yan Y, Zhang D, *et al.* Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy. *Theranostics.* 2025 June 12; 15 (14): 7090-126. <https://doi.org/10.7150/thno.114257>
42. Choi BD, Gerstner ER, Frigault MJ, Leick MB, *et al.* Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. *N Engl J Med.* 2024 Apr 10; 390 (14): 1290-8. <https://doi.org/10.1056/NEJMoal2314390>